I cant answer all of that mate, but for what its worth, for me,...

I cant answer all of that mate, but for what its worth, for me, its comparing two different companies using different tech - iNKT vs T-cell - allogenic v autologous (not withstanding the trials of Azer)

"Secondly, nobody knows how iNKT will perform but we already know, according to our clinical experts and the FDA, that IMU's techs work and are safe." - A study has been completed, peer reviewed and published for in-virto & in-vivo, vs T-Cell. Im still waiting for the nod to be able to post the info... but its out there if someone wants to find it.

Im not sure where the delay is... maybe i havent been in this sector long enough, but ALA seems to be on track with all their published timelines since ive been involved

Hopper is a bit on the nose for me, could be why sentiment is turning for the companies he is involved in, again, AIMO